IL311486A - 2'-Alkyl or 3'-Alkyl Modified Ribose Derivatives for Use in Intracorporeal Oligonucleotide Administration - Google Patents

2'-Alkyl or 3'-Alkyl Modified Ribose Derivatives for Use in Intracorporeal Oligonucleotide Administration

Info

Publication number
IL311486A
IL311486A IL311486A IL31148624A IL311486A IL 311486 A IL311486 A IL 311486A IL 311486 A IL311486 A IL 311486A IL 31148624 A IL31148624 A IL 31148624A IL 311486 A IL311486 A IL 311486A
Authority
IL
Israel
Prior art keywords
alkyl
oligonucleotides
vivo delivery
modified ribose
ribose derivatives
Prior art date
Application number
IL311486A
Other languages
English (en)
Hebrew (he)
Inventor
Weimin Wang
Xiaochuan Cai
Original Assignee
Sanegene Bio Usa Inc
Weimin Wang
Xiaochuan Cai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanegene Bio Usa Inc, Weimin Wang, Xiaochuan Cai filed Critical Sanegene Bio Usa Inc
Publication of IL311486A publication Critical patent/IL311486A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL311486A 2021-09-22 2022-09-22 2'-Alkyl or 3'-Alkyl Modified Ribose Derivatives for Use in Intracorporeal Oligonucleotide Administration IL311486A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163246870P 2021-09-22 2021-09-22
PCT/US2022/044377 WO2023049258A1 (en) 2021-09-22 2022-09-22 2'-alkyl or 3'- alkyl modified ribose derivatives for use in the in-vivo delivery of oligonucleotides

Publications (1)

Publication Number Publication Date
IL311486A true IL311486A (en) 2024-05-01

Family

ID=84053050

Family Applications (1)

Application Number Title Priority Date Filing Date
IL311486A IL311486A (en) 2021-09-22 2022-09-22 2'-Alkyl or 3'-Alkyl Modified Ribose Derivatives for Use in Intracorporeal Oligonucleotide Administration

Country Status (9)

Country Link
US (1) US20230241224A1 (cg-RX-API-DMAC7.html)
EP (1) EP4405368A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024534502A (cg-RX-API-DMAC7.html)
KR (1) KR20240082361A (cg-RX-API-DMAC7.html)
CN (1) CN118076619A (cg-RX-API-DMAC7.html)
AU (1) AU2022352676A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233113A1 (cg-RX-API-DMAC7.html)
IL (1) IL311486A (cg-RX-API-DMAC7.html)
WO (1) WO2023049258A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4705312A1 (en) * 2023-05-03 2026-03-11 Sanegene Bio USA Inc. Lipid-based conjugates for systemic, central nervous system, peripheral nervous system, and ocular delivery
AU2024301344A1 (en) * 2023-07-24 2026-01-29 Sanegene Bio Usa Inc. Lipid-based enhancement agent for rna delivery and therapy
CN116854754B (zh) 2023-09-01 2023-12-12 北京悦康科创医药科技股份有限公司 一种含有核糖环或其衍生结构的GalNAc化合物及其寡核苷酸缀合物
WO2025144872A2 (en) * 2023-12-29 2025-07-03 Adarx Pharmaceuticals, Inc. Nucleoside-derived lipids for drug delivery
WO2026041067A2 (en) 2024-08-20 2026-02-26 Sanegene Bio Usa Inc. Small interfering rna targeting myostatin (mstn) and uses thereof
WO2026046411A1 (en) 2024-09-02 2026-03-05 Sanegene Bio Usa Inc. Small interfering rna targeting plasminogen (plg) and uses thereof
WO2026092658A2 (en) 2024-10-31 2026-05-07 Sanegene Bio Usa Inc. Small interfering rna targeting amyloid beta precursor protein (app) and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
CA2039718C (en) 1989-08-31 2003-02-25 John J. Rossi Chimeric dna-rna catalytic sequences
US6365730B1 (en) 1990-06-19 2002-04-02 Gene Shears Pty. Limited DNA-Armed ribozymes and minizymes
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
AU649074B2 (en) 1990-10-12 1994-05-12 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Modified ribozymes
DE4216134A1 (de) 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
CA2135646A1 (en) 1992-05-11 1993-11-25 Kenneth G. Draper Method and reagent for inhibiting viral replication
JPH07509133A (ja) 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド 動物疾患の処置のための方法および剤
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5591317A (en) 1994-02-16 1997-01-07 Pitts, Jr.; M. Michael Electrostatic device for water treatment
US5631359A (en) 1994-10-11 1997-05-20 Ribozyme Pharmaceuticals, Inc. Hairpin ribozymes
AU3889595A (en) 1994-10-05 1996-05-02 Amgen, Inc. Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein
US5783683A (en) 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US5747470A (en) 1995-06-07 1998-05-05 Gen-Probe Incorporated Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
CA2518475C (en) 2003-03-07 2014-12-23 Alnylam Pharmaceuticals, Inc. Irna agents comprising asymmetrical modifications
EP2669377A3 (en) 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modified iRNA agents
AU2006279906B2 (en) 2005-08-10 2012-05-10 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
EP2229186A2 (en) 2007-12-04 2010-09-22 Alnylam Pharmaceuticals Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
RU2582235C2 (ru) 2010-12-29 2016-04-20 Ф.Хоффманн-Ля Рош Аг Низкомолекулярные конъюгаты для внутриклеточной доставки нуклеиновых кислот
WO2012142085A1 (en) * 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US8577565B2 (en) 2011-12-16 2013-11-05 GM Global Technology Operations LLC Limiting branch pressure to a solenoid valve in a fluid circuit
WO2015006740A2 (en) * 2013-07-11 2015-01-15 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
CA2940440A1 (en) * 2014-03-16 2015-09-24 MiRagen Therapeutics, Inc. Synthesis of bicyclic nucleosides
EP3131914B1 (en) * 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
EP3865576A1 (en) * 2014-12-15 2021-08-18 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids
CN106366146A (zh) * 2015-07-13 2017-02-01 中科云和(北京)生物医药科技有限公司 2’-双烷基取代的核苷类似物及用途
CN108137641B (zh) * 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
TWI912633B (zh) 2016-06-06 2026-01-21 美商愛羅海德製藥公司 5'-環-磷酸修飾之核苷酸
MX2019002075A (es) 2016-08-23 2019-07-01 Dicerna Pharmaceuticals Inc Composiciones que comprenden oligonucleotidos modificados reversiblemente, y sus usos.
WO2018045317A1 (en) 2016-09-02 2018-03-08 Dicerna Pharmaceuticals, Inc. 4'-phosphate analogs and oligonucleotides comprising the same
US20220389430A1 (en) * 2019-10-02 2022-12-08 Dicema Pharmaceuticals, Inc. Chemical modifications of small interfering rna with minimal fluorine content

Also Published As

Publication number Publication date
WO2023049258A1 (en) 2023-03-30
CN118076619A (zh) 2024-05-24
CA3233113A1 (en) 2023-03-30
KR20240082361A (ko) 2024-06-10
AU2022352676A1 (en) 2024-03-14
EP4405368A1 (en) 2024-07-31
US20230241224A1 (en) 2023-08-03
JP2024534502A (ja) 2024-09-20

Similar Documents

Publication Publication Date Title
IL288104B1 (en) Heterocyclic compounds, pharmaceutical preparations containing them and their use for the treatment of cancer
IL297849B1 (en) Composition for use in the treatment of APOL1-related disease
CY1119140T1 (el) Συνθεσεις αντικωδικευσης και μεθοδοι κατασκευης και χρησης τους
CL2007001427A1 (es) Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
IL199151A (en) Pyrimidine derivatives, their pharmaceutical preparations, their use in cancer treatment and their kits
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
IL196243A (en) [4,2,1] Triazole [3,4– a Pyridine Derivatives
IL195142A (en) Processed arylaimidazolone and triazolone, their preparation process, pharmaceutical preparations containing them for the treatment or prevention of diseases
IL192763A (en) History of pyrimidine, preparations containing them and used in the preparation of cancer drugs
WO2008133928A3 (en) Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders
IL207546A (en) Medical compounds for use in the treatment or prevention of bone and joint disease
PL2083837T3 (pl) Terapeutyczne zastosowanie co najmniej jednej neurotoksyny botulinowej do leczenia bólu wywołanego co najmniej jednym środkiem przeciwnowotworowym
IL206080A (en) A pharmaceutical preparation for the treatment and / or prevention of bone and joint disease
IL289167A (en) The history of 2h-indazole and their use in the treatment of diseases
PH12021551302A1 (en) COMPOUNDS AND THEIR USE FOR THE TREATMENT OF a1-ANTITRYPSIN DEFICIENCY
IL205608A (en) History of s-triazole-1-ram-benzamide and their use in the preparation of pain medication
IL291388A (en) Heterocyclic derivatives, pharmaceutical preparations and their use for the treatment or alleviation of cancer
IL289289A (en) History of polyaromatic ureas and their use in the treatment of muscle diseases
TWI365741B (en) Novel 1,3-dihydro-5-isobenzofurancarbonitrile derivatives and pharmaceutical composition thereof for the treatment of premature ejaculation
IL288924A (en) Casein kinase 1 inhibitors for use in the treatment of diseases associated with the expression of dux4 such as muscular dystrophy and cancer
IL307402A (en) The tercyclic derivatives, pharmaceutical compounds and their use in the treatment or amelioration of cancer
IL290532A (en) A hollow three-dimensional unit made of retinal tissue and its use in the treatment of retinopathy
IL265571B (en) A preparation containing ginger, Moira Poema, Paulinia Copena and l-arginine or l-citrulline for use in the treatment of orthopedic diseases
IL201426A (en) Drug combination and its use in the treatment of muscle loss
HK40108030A (en) 2'-alkyl or 3'- alkyl modified ribose derivatives for use in the in-vivo delivery of oligonucleotides